Two people drink the same cup of ayahuasca on the same night, in the same maloca, with the same shaman pouring. One spends six hours weeping into a bucket and rearranging the architecture of her grief. The other shrugs, says it was “interesting,” and goes to bed at midnight. What gives?

Set and setting explain part of it. Dose, diet, body weight, sleep, and the thousand invisible variables of mood account for more. But somewhere in that puzzle sits your DNA — the quiet hand that decides how your brain metabolizes a molecule, how many receptors it hands out for serotonin, and whether psychedelics are likely to feel like a doorway or a landslide. For anyone weighing a plant-medicine retreat, your genetic profile is worth at least a passing thought.

Genetic testing companies have started selling kits that claim to predict your psychedelic sensitivity. The science behind them is real, but it's also young, contested, and often oversimplified by marketing copy. So let's walk through five of the genes researchers keep coming back to — what each one actually does, what the research suggests, and how seriously you should take the results before you sign up for a ceremony.

Why genetics matter when you're considering a psychedelic retreat

Classical psychedelics — ayahuasca, psilocybin mushrooms, LSD, mescaline from San Pedro — all interact with the serotonin system. Ketamine works through a different mechanism. Ibogaine is its own beast entirely. Each of these substances passes through your liver, binds to specific receptors, and is then metabolized at a speed that varies wildly between individuals.

That variability has consequences. A “moderate” dose for one person can be a full ego-dissolution wallop for another. Someone with certain genetic variants may metabolize ketamine at half the normal rate, dragging out the experience for hours longer than the facilitator expected. Someone else may have a genetic profile that makes psychedelics genuinely risky — not unpleasant, but medically inadvisable.

None of this means you need a lab report before you go anywhere near plant medicine. People have been drinking ayahuasca for centuries without knowing what a serotonin receptor is. But if you're someone with a family history of psychosis, schizophrenia, or bipolar disorder, the genetic conversation gets serious fast. Here are the markers most often discussed in psychedelic research.

HTR2A: the serotonin receptor everyone talks about

If you've read anything about how psychedelics work in the brain, you've met the 5-HT2A receptor. It's the docking site for psilocybin, LSD, DMT (the active alkaloid in ayahuasca), and mescaline. When these molecules fit into the receptor, they make cortical neurons fire in a chaotic, exuberant pattern — the neural signature, scientists believe, of the psychedelic state itself.

The HTR2A gene codes for that receptor. Roughly one in five people carries a variant that produces more receptors than average, which may translate into greater sensitivity. More docking sites, more activity, potentially a more intense trip from the same dose. It's not a guarantee — sensitivity is shaped by many factors — but it's a plausible piece of the puzzle.

Practically, what does this mean? If you suspect you're a sensitive responder (and many people figure this out the hard way), start lower than the standard ceremonial dose and tell your facilitator. A good shaman or guide will respect that. A facilitator who pushes you to drink more than feels right is a red flag regardless of your genes.

CYP2B6: how fast you clear ketamine from your system

Ketamine isn't a classical psychedelic, but it's increasingly part of the broader conversation around psychedelic-assisted therapy and addiction treatment. The CYP2B6 gene encodes a liver enzyme that breaks ketamine down. About 10 to 20 percent of people have a variant that slows that process dramatically — they clear the drug roughly half as fast as everyone else.

For these slow metabolizers, a standard dose lingers. The dissociation lasts longer, the hangover is heavier, and the risk of side effects — drowsiness, confusion, unsettling hallucinations — climbs. The route of administration matters here too: intramuscular injection hits harder than nasal or oral dosing, which is part of why reputable clinics start cautious and titrate up.

If you're booking a ketamine-assisted therapy session and you've ever had outsized reactions to anesthesia or other sedatives, mention it. That history is often a clue.

C4A, NRG1, and DISC1: the psychosis-risk markers

This is where things get heavier. Three genes — C4A, NRG1, and DISC1 — have all been linked, with varying strength of evidence, to increased risk of psychosis, schizophrenia, and bipolar disorder. They influence brain development through different mechanisms:

• C4A is involved in synaptic pruning — the adolescent brain's quiet renovation project, trimming unused neural connections. People with extra copies of the gene may prune too aggressively, which researchers have tied to elevated mental-health risk.
• NRG1 (neuregulin 1) promotes new neuron growth and underpins learning and memory. A specific genotype, found in roughly 15 percent of the population, overexpresses the protein in ways that have been associated with psychosis risk.
• DISC1 — “disrupted in schizophrenia 1” — was one of the earliest genes flagged as a mental-health risk marker across populations. The research has been both challenged and reinforced over the past decade, but the link remains taken seriously.

Why does this matter for psychedelics? Because powerful serotonergic drugs can, in rare cases, trigger or unmask a latent psychotic episode in people already vulnerable. Most retreat centers screen for personal and family history of schizophrenia, bipolar disorder, and psychosis — and they turn people away who disclose those conditions. That screening exists for good reason. If you have a parent, sibling, or grandparent with one of these diagnoses, talk to a psychiatrist before you book anything. A genetic test is not a substitute for that conversation; it's at best a supplement to it.

How much should you actually trust a psychedelic DNA test?

The honest answer: take the results as one signal among many, not as a verdict. Genetic testing for psychedelic sensitivity is a young field. Some of the conclusions marketed by direct-to-consumer companies rest on a small handful of studies, and a few have been called out by researchers as overstated or based on outdated science. Reports often come with disclaimers that the results are not medical advice — and that disclaimer is doing real work.

What a test can usefully tell you:

1. Whether you might metabolize certain substances unusually slowly.
2. Whether your serotonin receptor profile may make you a more sensitive responder.
3. Whether you carry markers associated with elevated psychiatric risk — information worth discussing with a clinician.

What it can't tell you: whether you'll have a healing experience, whether you'll fall apart, whether the ayahuasca will show you the face of your grandmother or a tunnel of geometric snakes. Genes are one input. Your psychological history, your relationship with the facilitator, your preparation, the integrity of the lineage running the ceremony — all of these matter just as much, and most of them matter more.

What to actually do before booking a retreat

Skip the genetic test if you want. Buy one if you're curious. Either way, the practical checklist for anyone considering a plant-medicine experience looks roughly the same:

• Be honest about your psychiatric history. Personal or family history of schizophrenia, bipolar disorder, or psychosis is a hard stop for classical psychedelics at most reputable centers.
• Disclose every medication you're taking. SSRIs, MAOIs, lithium, and many other drugs interact dangerously with ayahuasca in particular. A serious retreat will ask. If they don't ask, walk away.
• Vet the facilitators. Years of experience, lineage, references from past participants, medical screening protocols, an emergency plan. These are not optional.
• Plan for integration. The ceremony is the easy part. The weeks afterward — making sense of what surfaced, changing the patterns the medicine illuminated — is where the actual work happens.
• Start with a conservative dose. Especially if you suspect you're sensitive, or if it's your first time. You can always go deeper next ceremony. You can't undo a dose that was too much.

Psychedelics, used carefully, are showing real promise for addiction recovery, depression, PTSD, and the kind of stuck life patterns that talk therapy struggles to crack. Master plants like ayahuasca, San Pedro, and iboga have helped many people loosen the grip of things they couldn't loosen on their own. But the keyword in that sentence is carefully. The same molecules that open doors can also kick down walls you weren't ready to lose.

If you've read this far and you're still curious about taking the next step, a range of vetted ayahuasca and psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly, with good information, and with a clear sense of why you're going.